This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Reasons Why You Should Add HCP to Your Portfolio Right Now
by Zacks Equity Research
HCP's efforts to expand its medical office and life-science portfolio, a diversified and high-quality portfolio and favorable demographic trends make it an attractive pick.
HCP Surpasses Q2 FFO & Revenue Estimates, Raises Outlook
by Zacks Equity Research
HCP witnesses rise in revenues and net operating income in the second quarter of 2019.
HCP (HCP) Q2 FFO and Revenues Beat Estimates
by Zacks Equity Research
HCP (HCP) delivered FFO and revenue surprises of 2.33% and 9.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Key Factors Setting the Tone for HCP This Earnings Season
by Zacks Equity Research
Focus on life-science and MOB portfolio will likely enable HCP to witness decent growth in Q2. However, prevalent challenges in the senior housing market are a spoilsport.
Ventas (VTR) to Buy Seniors Housing Portfolio Worth $1.8B
by Zacks Equity Research
Acquisition of seniors housing portfolio valued at $1.8 billion, including construction in progress, will likely help Ventas (VTR) in diversifying its assets, business model and operator base.
Why Is HCP (HCP) Up 2.8% Since Last Earnings Report?
by Zacks Equity Research
HCP (HCP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HCP Amends and Restates Credit Facility, Boosts Strength
by Zacks Equity Research
HCP's amended and restated credit helps increase the size of the facility, extend the maturity date, lower the borrowing costs and boost financial flexibility.
CORR vs. HCP: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CORR vs. HCP: Which Stock Is the Better Value Option?
HCP's Q1 FFO Surpasses, Revenues Miss Estimates, NOI Up
by Zacks Equity Research
HCP's first-quarter 2019 results indicate decent performance of the company's life-science and medical-office segments. Yet, tepid performance of seniors-housing portfolio remains a drag.
HCP (HCP) Q1 FFO Beat Estimates
by Zacks Equity Research
HCP (HCP) delivered FFO and revenue surprises of 2.33% and -1.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Senior Housing Softness Impact HCP in Q1 Earnings?
by Zacks Equity Research
HCP's premium MOB and life-sciences portfolio will likely perform well in first-quarter 2019, mitigating the challenges tormenting the senior housing market.
Healthcare Realty Completes MOB Buyouts in Potential Markets
by Zacks Equity Research
Healthcare Realty (HR) completes purchase of four properties, amid soaring popularity for medical-office buildings.
Why Is HCP (HCP) Up 1.2% Since Last Earnings Report?
by Zacks Equity Research
HCP (HCP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Healthcare Realty (HR) Prices Offering of 3.25M Common Stock
by Zacks Equity Research
Healthcare Realty's (HR) latest public offering of common stock will improve its financial flexibility and provide ample scope for deploying capital in accretive acquisitions.
HCP Meets Q4 FFO Estimates, Misses on Revenues, Issues View
by Zacks Equity Research
HCP's fourth-quarter 2018 results marred by continued decline in senior-housing operating portfolio cash net operating income.
HCP (HCP) Q4 FFO Match Estimates
by Zacks Equity Research
HCP (HCP) delivered FFO and revenue surprises of 0.00% and -1.33%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Operator Transitions Hit HCP's Occupancy in Q4 Earnings?
by Zacks Equity Research
As HCP remains focused on reducing its Brookdale-portfolio concentration, we anticipate the company to report lower portfolio occupancy in the fourth quarter.
Why Trending Outpatient Care is a Boon for Healthcare REITs
by Devyani Chamria
Amid shift of care to low-cost setting, medical office buildings (MOBs) and outpatient facilities have been creating opportunities for healthcare REITs to park their money.
HCP's Unsecured Debt Rating Notched Up to Baa1 by Moody's
by Zacks Equity Research
HCP's senior unsecured debt rating has been bumped up by a notch to Baa1 by Moody's. Moreover, the rating firm's outlook for the company has been maintained at stable.
LXP vs. HCP: Which Stock Is the Better Value Option?
by Zacks Equity Research
LXP vs. HCP: Which Stock Is the Better Value Option?
HCP Prices Upsized Public Offering of 15M Common Shares
by Zacks Equity Research
HCP increases public offering of common stock to 15 million shares, and enters into a forward sale agreement for 13 million shares as well.
HCP (HCP) Up 2.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
HCP (HCP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HPT vs. HCP: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HPT vs. HCP: Which Stock Is the Better Value Option?
HCP (HCP) Surpasses Q3 FFO Estimates
by Zacks Equity Research
HCP (HCP) delivered FFO and revenue surprises of 2.33% and -0.31%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
HCP Tops Q3 FFO Estimates on NOI Growth, Misses on Revenues
by Zacks Equity Research
HCP's third-quarter performance indicates year-over-year growth in three-month cash SPP net operating income (NOI) for the company's total portfolio.